基因重组Echistatin发酵工艺的优化

目的:利用基因工程方法对一种蛇毒锯鳞蝰素蛋白的发酵纯化工艺进行优化,以提高目的蛋白的产量和纯度。方法:对工程菌进行发酵培养并诱导表达,研究不同的培养基、不同补料方式、溶解氧浓度、培养和诱导时间对工程菌产量和目的蛋白表达量的影响,利用几丁质亲和层析纯化Ecs融合蛋白,通过合适温度和pH裂解融合蛋白得到Ecs纯品,并鉴定和检测Ecs活性。结果:经过高密度发酵优化后,菌体湿重可达110g/L,目的蛋白表达量约占总蛋白的40%;亲和层析纯化后,得到Ecs单体,得率为68mg/L发酵液。生物学活性分析显示,重组Ecs能有效抑制血小板的聚集,其活性与天然Ecs相似。结论:通过发酵和纯化工艺优化,大大提高了目的蛋白产量,为进一步规模化研究和生产奠定了基础。     

乳酸菌蛋白质分泌表达研究进展

食品级乳酸菌不仅是食品或消化道中传递异源蛋白质的合适的候选菌,在工业发酵中还可用于生产蛋白质。在过去20多年中,人们设计了许多乳酸菌蛋白质表达和标记系统,这些系统已用在乳酸菌工程菌的细胞内或细胞外生产各种细菌、病毒和真核生物来源的蛋白质。在目的蛋白生产和发酵中,分泌表达由于可持续培养和简化纯化步骤并使目的蛋白与其靶位相互作用而优于细胞质表达。目前只有少数研究报道了目的蛋白在乳酸菌细胞内或分泌表达产量的比较,研究表明分泌表达比细胞质表达更优越。     

离子交换色谱法对大肠杆菌表达的人重组骨形态发生蛋白-7的纯化

带有BMP 7基因的大肠杆菌可以用来高量表达重组的人骨形态发生蛋白 7。升温诱导表达后 ,每升培养液大约可得到菌体湿重 3g ,其中目的蛋白约占菌体总蛋白量的 40 %。裂解离心 ,用低浓度变性剂洗涤初步纯化包涵体 ,上清中无目的蛋白损失 ,目的蛋白纯度提高到 60 %,将包涵体溶解于高浓度变性剂溶液中 ,然后在不同条件下用离子交换色谱法对变性状态下的蛋白质进行纯化 ,绝大部分杂蛋白被除去 ,目的蛋白纯度达 95 %以上 ,改变条件 ,可以减少rhBMP 7损失。并做Westernblot对目的蛋白进行特异性鉴定。     

离子交换色谱法对大肠杆菌表达的人重组骨形态发生蛋白-7的纯化

重组大肠杆菌高量表达重组人骨形态发生蛋白-7(rhBMP-7),每升培养液约得到湿菌体3g,其中目的蛋白约占菌体总蛋白量的40％。裂解离心,用低浓度变性剂洗涤初步纯化包涵体,上清中无目的蛋白损失;将包涵体溶解于高浓度变性剂溶液中,目的蛋白纯度提高到60％;然后在不同条件下用离子交换色谱法对变性状态下的蛋白质进行纯化,绝大部分杂蛋白被除去,目的蛋白纯度达95％以上;改变条件,可以减少rhBMP-7损失;用Western blot对目的蛋白进行特异性鉴定。     

蛇毒锯鳞蝰素融合蛋白的发酵与纯化

研究大肠杆菌表达重组蛇毒锯鳞蝰素(Echistatin,Ecs)融合蛋白的发酵和纯化工艺。将Ecs基因插入表达载体pTXB1,转化E.coliBL21(DE3)构建工程菌。对工程菌进行补料分批培养并诱导表达,研究培养基、培养和诱导时间对工程菌生长和目的蛋白表达的影响,几丁质亲和层析纯化Ecs融合蛋白,经DTT裂解后,检测Ecs活性。发酵后菌体湿重可达75g/L,融合蛋白表达量约占总蛋白的35%,重组质粒在BL21宿主菌中传代稳定。亲和层析纯化后,得到Ecs单体,得率为28mg/L发酵液。生物学活性分析显示,重组Ecs能有效抑制血小板的聚集,其活性与天然Ecs相似。优化了Ecs融合基因工程菌的发酵和纯化条件,为规模化生产奠定基础。     

重组L-门冬酰胺酶工程菌的表达和PEG的化学修饰

目的提高重组L-门冬酰胺酶(rL-ASP)工程菌的表达量,分离纯化rL-ASP并对之进行PEG化学修饰。方法将带有编码rL-ASP的基因的质粒(pKA)导入不同的宿主菌中,挑出高表达菌株,同时优化发酵培养基,分离纯化获得的高纯度rL-ASP再用PEG进行化学修饰,SDS-PAGE检测修饰效果。结果在pH7.0的条件下,宿主菌为JMl09的工程菌pKA/JMl09酶活力最高,三角瓶振摇培养的酶活力可达216×103IU/L;发酵罐发酵培养,酶活力达312×103IU/L。纯化后的rL-ASP比活力为220IU/mg,rL-ASP经过PEG化学修饰生成rL-ASP-PEG,分子量发生改变。结论改变目标蛋白表达的宿主菌和优化发酵工艺,提高了rL-ASP的表达量,纯化的rL-ASP经过PEG化学修饰后分子量增大。     

甲醇酵母分泌表达重组人干扰素α1b纯化工艺的建立

建立适合大规模、低成本生产重组人干扰素α1b(Recombinanthumaninterferon α1b ,rhIFN α1b)的纯化工艺。采用高效分泌表达rhIFN α1b的甲醇酵母工程菌发酵 ,收集离心后的上清液 ,超滤脱盐 ,经离子交换柱和分子筛柱层析纯化。纯化的rhIFN α1b的纯度为 98%以上 ,比活性 2 .4× 10 7IU/mg ,活性回收率 14 % ,相对分子质量 1980 0和等电点 5 .0。经检测 ,rhIFN α1b蛋白N 端 15个氨基酸序列与正常对照完全符合。该纯化工艺简便 ,时程短 ,重复性好 ,适合于大规模生产     

基因工程菌的发酵研究

本文对大肠杆菌表达的rhGM - CSF 工程菌的发酵条件进行了详细的研究, 探讨了发酵条件对工程菌表达外源蛋白量的影响, 优化了影响发酵的各种条件, 形成了一套工程菌发酵表达外源蛋白的工艺, 并从工业化角度对工程菌的高密度高表达间的关系进行了探讨。     

rhEPO-Fc融合蛋白的表达、纯化及质量研究

用无血清培养基培养分泌表达rhEPO-Fc融合蛋白的工程细胞株MY06（CHO细胞）,收集发酵培养上清,通过离心、过滤、亲和层析、离子交换层析、分子筛等方法对目的蛋白进行纯化,通过lowry法、SDS-PAGE、Western-blot、HPLC、ELISA及IEF等方法研究目的蛋白质量,以建立rhEPO-Fc融合蛋白的发酵、纯化工艺,并探寻该融合蛋白的质量检测方法。结果通过该工艺rhEPO-Fc蛋白表达量高达2g/L,蛋白纯化得率达45%以上,纯度可达98％以上,相对分子质量约为60KD,t1/2长达38h,免疫印迹证明具有天然EPO的免疫原性。研究结果表明该生产工艺可获得rhEPO-Fc的高效表达,纯化得率高,质量检验方法稳定可靠,适用于大规模生产。     

重组枯草芽孢杆菌发酵生产乳铁蛋白N叶工艺优化北大核心CSCD

为实现乳铁蛋白N叶的大规模制备,本研究对表达乳铁蛋白N叶的工程菌枯草芽孢杆菌pMA0911-D60Y/Y92D进行了发酵工艺的优化。确定了最佳的培养条件:以葡萄糖为最佳碳源,以胰蛋白胨为最佳氮源,在pH 7.0、温度28℃、发酵25.5 h条件下诱导表达目的蛋白,目的蛋白的IOD值高达68.03%。在10L发酵罐上对重组菌株的发酵条件进行优化,获得如下的最佳发酵工艺,即采用300 r/min转速,0-7 h时,在pH 7.5、30℃条件下培养菌体;7-25 h时,在pH 7.0、28℃条件下诱导表达目的蛋白。发酵结束后,收集细胞并破碎后取上清液用HisTrapHP亲和层析及SuperdexTM200(10/300GL)亲和层析法对细胞上清液进行纯化至均一条带,获得了纯度>94%的重组乳铁蛋白N叶,1 L菌体能制备23.5 mg纯蛋白。本研究为重组牛乳铁蛋白N-叶的高效制备奠定了基础。     

Optimized procedure for renaturation of recombinant human bone morphogenetic protein-2 at high protein concentration

The human gene encoding the mature form of bone morphogenetic protein-2 (hBMP-2), a dimeric disulfide-bonded protein of the cystine knot growth factor family, was expressed in recombinant Escherichia coli using a temperature-inducible expression system. The recombinant protein was produced in the form of cytoplasmic inclusion bodies and the effect of different variables on the renaturation of rhBMP-2 was investigated. In particular, variables such as pH, redox conditions, protein concentration, temperature, the presence of different types of aggregation suppressors, and host cell contaminants were studied with respect to their effect on aggregation during refolding and on the final renaturation yield of rhBMP-2. It is shown that the renaturation yield is particularly sensitive to pH, temperature, protein concentration, and the presence of aggregation suppressors. In contrast, little effect of the redox conditions and the ionic strength on the renaturation yield was observed, as equal yields were obtained in a broad range of reduced to oxidized glutathione ratios and concentrations of NaCl, respectively. The aggregation suppressor 2-(cyclohexylamino)ethanesulfonic acid (CHES) proved to be superior with respect to the final renaturation yield, although, in comparison to the more common arginine, it was less efficient in preventing aggregation of rhBMP-2 during refolding. Detergent washing of inclusion bodies was sufficient, as further purification of rhBMP-2 prior to refolding was without effect on the final renaturation yield. An increase in the concentration of renatured rhBMP-2 was achieved by a pulsed refolding procedure by which up to a total amount of 2.1 mg mL(-1) rhBMP-2 could be transferred in seven pulses into the renaturation buffer with an overall refolding yield of 38%, corresponding to 0.8 mg mL(-1) renatured dimeric rhBMP-2. Furthermore, a simplified purification procedure is presented that also includes freeze-drying for long-term storage of biologically active rhBMP-2. Finally, it is shown that the appearance of rhBMP-2 variants could be avoided by using a host strain overexpressing rare codon tRNAs.     

Optimized procedure for expression and renaturation of recombinant human bone morphogenetic protein-2 at high protein concentrations

A prokaryotic expression system has been used to produce recombinant human bone morphogenetic protein-2 (rhBMP-2). However, low rhBMP-2 yields and protein loss during purification and renaturation are the hurdles in the clinical application. Previous studies have indicated that variables such as temperature, host cell, salt concentration, and culture time affect the final rhBMP-2 yield. The optimization of these conditions in an Escherichia coli culture yielded 28.258 mg of rhBMP-2 per liter of culture. To reduce rhBMP-2 loss during purification and renaturation, we performed purification before renaturation in the prokaryotic expression system instead of using the traditional renaturation-before-purification approach. rhBMP-2 was separated on a Sephacryl S-300 HR column and eluted from a DEAE-Sepharose Fast Flow column. The collected protein was refolded by dialysis with urea buffer, which was followed by dialysis with ultrapure water. The purified rhBMP-2 dimer significantly increased alkaline phosphatase (ALP) activity and osteogenic activity in the femoral muscle and showed the same level of bone-forming activity as natural BMP-2. This optimized procedure for expression and renaturation of rhBMP-2 has potential clinical applications.     

重组人骨形态发生蛋白-7与脱钙骨基质复合物双重骨诱导作用的生物学评价

将不同剂量的重组人骨形态发生蛋白-7(rhBMP-7)与脱钙骨基质(DBM)分别复合后,植入小鼠股部内侧肌间隙,三周后取材,通过组织学检查、碱性磷酸酶(ALP)及钙含量的测定比较各组的骨诱导活性。结果显示,三组复合物均有骨组织生成,中、高剂量组可见骨小梁、板层骨和原始骨髓腔,血管和骨髓丰富;低剂量组的成骨量明显少于中、高剂量组,且新骨的成熟度低于其他两组,DBM少部分吸收;单独植入rhBMP-7组有编织骨形成;而DBM组可见成骨细胞的聚集。rhBMP-7/DBM复合组在ALP和Ca含量水平上与同等剂量的两对照组相比均有显著性差异(P<0.01),而rhBMP-7三种剂量之间均有显著性差异(P<0.01)。这充分说明DBM作为rhBMP-7的合适载体,具有缓释作用,且二者复合可起到双重骨诱导活性;而且rhBMP-7的骨诱导活性具有一定的剂量依赖性。     

重组人骨形态发生蛋白-6的表达、纯化及其活性分析

利用RT-PCR从人胎盘组织中获取BMP-6成熟肽的cDNA 片段,并克隆到表达载体pET-15b中, 构建hBMP_6成熟肽的非融合蛋白表达质粒pET-BMP6,转化E.coli BL21（DE3）。IPTG 诱导4h后,工程菌高表达rhBMP-6成熟肽,在SDS-PAGE上出现预期的新蛋白带(≈15kD), 约占菌体总蛋白的10%,表达产物以包涵体形式存在。分离和纯化的包涵体溶解于8 mol/L尿素,在变性溶解状态下经阳离子交换层析,得到目的蛋白纯度达95%以上。再经稀释复性后,约80%的rhBMP-6形成同源二聚体。体外活性分析结果显示：rhBMP-6可以提高C3H10T1/2 细胞碱性磷酸酶活性及促进I型胶原、Osterix（Osx）和骨钙素（Osteocalcin）等成骨细胞表型转化标记基因mRNA的表达,证明制备的rhBMP_6具有诱导非骨源性细胞分化成为成骨细胞的作用。     

Expression and purification of recombinant human bone morphogenetic protein-7 (rhBMP-7) in <Emphasis Type="Italic">Bacillus subtilis</Emphasis>

The polypeptide representing the mature part of human bone morphogenetic protein-7 (BMP-7) was cloned and efficiently expressed in Bacillus subtilis. Recombinant B. subtilis had a clear band for rhBMP-7, a homodimeric protein with an apparent molecular weight of 15.4 kDa and produced 350 pg rhBMP-7/mL of culture medium. The extracellular and intracellular rhBMP-7 was purified in two steps using a fast performance liquid chromatography (FPLC) system with an ion-exchange column and a gel filtration column. The extracellular rhBMP-7 had a purity of 57.1% and a yield of 58.8%, while the purity of the intracellular rhBMP-7 was 36.2% with a yield of 51.4%. The rhBMP-7 produced in this work also stimulated alkaline phosphatase (ALP) activity in a dose-dependent manner, i.e. 2.5- and 8.9-fold at 100 and 300 ng rhBMP-7/mL, respectively, and showed intact biological activity.     

EXPRESSION AND PURIFICATION OF RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-7 IN Escherichia coli

Bone morphogenetic protein-7 (BMP-7) is a multifunctional cytokine of the transforming growth factor β superfamily, which induces bone formation and plays an important role during bone tissue repair and embryonic development. In this study, human BMP-7 (hBMP-7) cDNA was cloned and expressed in Escherichia coli, and its yield was approximately 30% of the total bacterial protein. After the bacteria were lysed by ultrasonication and repeated washing, inclusion bodies were extracted and dissolved using a high-strength denaturant. The monomer of rhBMP-7 was purified by ion-exchange chromatography, and the purity coefficient was approximately 96%. The protein was renatured with refolding buffers at different pH values. The renatured rhBMP-7 dimer protein in this study increased the alkaline phosphatase activity of NIH3T3 cells. This study may be helpful for the in vitro production and biomedical application of rhBMP-7 protein expressed in an E. coli expression system.     

Production of the recombinant human bone morphogenetic protein-2 in Escherichia coli and testing of its biological activity in vitro and in vivo

Bone morphogenetic protein-2 (rhBMP-2) represents the osteoinductive protein factor which plays a dominant role in growth and regeneration of a bone tissue. In clinical practice the bone grafting materials on the basis of rhBMP-2 are widely applied; the Russian analogues of similar materials are not produced. The fragment of the bmp2gene coding for a mature protein was cloned in Escherichia coli. The effective overproducing strain of rhBMP-2 was created on a basis of the E. coli BL21 (DE3). The rhBMP-2 production was about 25% of total cell protein. The biologically active dimeric form of rhBMP-2 was obtained by isolation and purification of protein from inclusion bodies with subsequent refolding. The rhBMP-2 sample with more than 80% of the dimeric form was obtained, which is able to interact with specific antibodies to BMP-2. Biological activity of the received rhBMP-2 samples was shown in the in vitro experiments by induction of alkaline phosphatase synthesis in C2C12 and C3H10T1/2 cell cultures. On model of the ectopic osteogenesis it was shown that received rhBMP-2 possesses biological activity in vivo, causing tissue calcification in the place of an injection. The protein activity in vivo depends on way of protein introduction and characteristics of protein sample: rhBMP-2 may be introduced in an acid or basic buffer solution, with or without the carrier. The offered method of rhBMP-2 isolation and purification results in increasing common protein yield as well as the maintenance of biologically active dimeric form in comparison with the analogues described in the literature.     

溶氧反馈分批补料高密度培养人骨形成蛋白-2工程菌

对表达人骨形成蛋白－2成熟肽的基因工程大肠杆菌E.coli DH5α/pDH-B2m在500mL摇瓶中进行了培养条件的摸索实验,并在此基础上扩大至NBS Bioflo IV20L发酵罐,利用溶氧反馈－分批补料培养技术：在培养过程中保持适当的溶解氧（40％）,以溶氧值在线反馈控制搅拌速度及流加补料培养基,使细菌保持适当的比生长率,成功地进行了工程菌的高密度培养,最终菌体密度达OD600＝57,每升干菌量22.8g,目的蛋白的表达量占细菌总蛋白的30％,人骨形成蛋白－2成熟肽的理论产率达到3.59g/L。     

Effects of bone morphogenetic protein-7 stimulation on osteoblasts cultured on different biomaterials

The objective of the present study was to investigate the effects of an in vitro stimulation of human osteoblasts by recombinant human bone morphogenetic protein-7 (rhBMP-7) on the collagen types and the quantity of the collagen cross-links synthesized in a three-dimensional culture on various biomaterials for bone replacement. Trabecular bone chips were harvested from human iliac crests, and cell cultures were established at standard conditions. One hundred and fifty nanograms per milliliter of rhBMP-7 was added. For the second passage a cell scraper was used to bring the cells into suspension, and 100 microl osteoblasts (at a density of 3.3 x 10(5)) were transferred onto nine blocks of either Bio-Oss, Tutoplast, or PepGen p-15. Blocks incubated with cells that were not treated with rhBMP-7 served as controls. Cell colonization of the biomaterials was observed by scanning electron microscopy (SEM) and transmission electron microscopy (TEM) after a period of 2, 4, and 6 weeks. Throughout the experiment medium, supernatants were collected and collagen was characterized by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Finally, the collagen cross-link residues hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP) were quantified by HPLC. Within 4 weeks the cells became confluent on all of the studied biomaterials. All samples synthesized bone specific LP and collagen type I. However, in rhBMP-7-stimulated samples, the amount of HP and LP found was increased by 45% compared to non-stimulated samples. Cell proliferation and collagen synthesis was similar on the different biomaterials, but was consistently reduced in specimen not stimulated with rhBMP-7. In vitro stimulation of osteoblasts on Bio-Oss, Tutoplast, or PepGen p-15 with rhBMP-7 and subsequent transplantation of the constructs might lead to an enhanced osseointegration of the biomaterials in vivo.